Cytokine Induced Memory-Like Natural Killer Cells
Chromophobe Renal Cell Carcinoma
Explore 10 assets in Chromophobe Renal Cell Carcinoma →Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Dana-Farber Cancer Institute
Modality
Cell therapy
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06318871CT.gov Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chromophobe Renal Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cytokine Induced Memory-Like Natural Killer Cells (this asset) | Dana-Farber Cancer Institute | Early P1 | C · 39 |
| Cabozantinib | Bradley A. McGregor, MD | P2 | B |
| Pazopanib | Mayo Clinic | P2 | B |
| Nivolumab | Bradley A. McGregor, MD | P2 | CCC |
| Ipilimumab | Bradley A. McGregor, MD | P2 | CCC |
| Sorafenib | National Cancer Institute (NCI) | P1/2 | CCC |
| nn3201 | Novelty Nobility, Inc. | P1 | CC |
| Glutamine | University of Texas Southwestern Medical Center | N/A | D |
| Glucose, Anhydrous | University of Texas Southwestern Medical Center | N/A | D |
+3 more in the Chromophobe Renal Cell Carcinoma cohort
Other indications for Cytokine Induced Memory-Like Natural Killer Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myeloproliferative Neoplasm | — | P1 | CC · 41 |
| Myeloid Leukemia | — | P1 | CC · 41 |
| Renal Carcinoma | — | Early P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cytokine Induced Memory-Like Natural Killer Cells in Chromophobe Renal Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cytokine-induced-memory-like-natural-killer-cells-chromophobe-renal-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →